# CINVANTI® (cinvanti) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/cinvanti

> CINVANTI® (cinvanti), sponsored by HERON THERAPEUTICS, INC. /DE/ (HRTX): 1 recorded catalyst.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | CINVANTI® (cinvanti) |
| Codes |  |
| Sponsor | HERON THERAPEUTICS, INC. /DE/ (HRTX) https://sec-api.dev/companies/hrtx/catalysts |
| Indications |  |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### December 12, 2023: NDA/BLA submission

- Status: completed. Date confidence: exact.
- First seen 2024-11-12, last confirmed 2024-11-12.
- SEC Form 10-Q (accession 0000950170-24-124698): "On December 12, 2023, the Company received a Notice Letter (the "Slayback Notice") from Slayback Pharma LLC ("Slayback") advising that Slayback had submitted an NDA under Section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act to the FDA seeking approval to manufacture, use or sell a generic version of CINVANTI in the U.S. ("Slayback's NDA") prior to the" https://www.sec.gov/Archives/edgar/data/818033/000095017024124698/hrtx-20240930.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/cinvanti.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "CINVANTI® (cinvanti) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/cinvanti

```bibtex
@misc{secapidev_pdufa_cinvanti_20261116,
  title        = {CINVANTI® (cinvanti) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/cinvanti}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_cinvanti_20261116","title":"CINVANTI® (cinvanti) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/cinvanti","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
